Claims for Patent: 9,315,826
✉ Email this page to a colleague
Summary for Patent: 9,315,826
Title: | Nucleic acids containing a synthetic codon-optimized Sin Nombre virus full-length M gene |
Abstract: | The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus. |
Inventor(s): | Hooper; Jay (New Market, MD) |
Assignee: | The United States of America as rep. by the Sec\'y of the Army, for U.S. Army Medical Research Institute of Infectious Diseases (Washington, DC) |
Application Number: | 13/982,606 |
Patent Claims: | 1. An isolated nucleic acid sequence set forth in SEQ ID NO:1.
2. The isolated nucleic acid sequence of claim 1, wherein the sequence is SEQ ID NO:2. 3. The isolated nucleic acid sequence of claim 2, wherein the sequence is SEQ ID NO:3 4. A recombinant DNA construct comprising: (i) a vector, and (ii) the DNA fragment comprising the nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, operably linked to a promoter sequence. 5. The recombinant DNA construct of claim 4 wherein the promoter is the cytomegalovirus promoter operably linked to Intron A, or wherein the promoter is the beta-actin promoter or the SV40 promoter. 6. The recombinant DNA construct of claim 4 wherein said construct is pWRG/SN-M(opt). 7. The recombinant DNA construct of claim 4, wherein the vector is a recombinant adenovirus or recombinant vesicular stomatitis virus, or alphavirus replicon. 8. A DNA cassette comprising either SEQ ID NO:2 or SEQ ID NO:3, linked to a promoter operable in a eukaryotic expression system. |
Details for Patent 9,315,826
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2039-02-26 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.